CALGARY, April 30 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced its financial results and highlights for the three month period ended March 31, 2008.
"We are currently enrolling or recruiting patients in a total of nine
clinical trials, four exploring the use of REOLYSIN(R) as a monotherapy,
and five exploring the use of REOLYSIN(R) in combination with a variety of
chemotherapies, immune modulation and radiotherapy," said Dr. Brad
Thompson, President and CEO of Oncolytics. "In 2008, we expect to report
interim or final results on a number of our ongoing clinical trials. We are
rapidly moving toward the point where we can expect to make pivotal
clinical trial decisions about REOLYSIN(R). It is an exciting time for
Oncolytics and our shareholders."
First Quarter Highlights
Significant Clinical Advances
- Met the criteria to expand to full enrolment of 52 patients in our
U.S. Phase II sarcoma trial after the third patient treated in the
trial experienced stable disease by RECIST criteria for more than
- In early April, our collaborators presented positive interim results
from our U.K. combination REOLYSIN(R) and paclitaxel/carboplatin
trial at the British Society of Gene Therapy conference in Edinburgh.
Three head and neck patients evaluated to date have had excellent
clinical and radiological responses without appreciable toxicity.
- The U.S. National Cancer Institute filed a protocol with the U.S. FDA
to conduct a Phase I/II ovarian, peritoneal and fallopian tube cancer
trial. The trial is currently recruiting patients.
- Research characterizing immune system responses to REOLYSIN(R) in our
U.K. Phase I systemic administration trial was published in the
March 6 issue of Gene Therapy.
|SOURCE Oncolytics Biotech Inc.|
Copyright©2008 PR Newswire.
All rights reserved